ty21a
Vaccineexperimental
Ty21a is a live attenuated bacterial vaccine that protects against typhoid. First licensed in Europe in 1983 and in the United States in 1989, it is an orally administered, live-attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been deleted so as to render it harmless but nevertheless immunogenic. It is one of the three typhoid vaccines currently recommended by the World Health Organization. — Wikipedia
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01405521)
Timeline
Indications
Mechanism of action
- Salmonella typhiImmunity, active
Salmonella typhi immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTy21a ↗
- NCATS0MZI008M96 ↗
Also known as
- ty21a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04543877 | Early Phase 1 (Phase 1) | Feb 1, 2022 | United States Department of Agriculture, University of Minnesota |
| NCT03421236 | Phase 1 | Mar 1, 2018 | University of Lausanne |
| NCT01405521 | Phase 2 | Dec 1, 2011 | University of London, University of Maryland, University of Oxford, Wellcome Trust |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| United States Department of Agriculture | Government | 1 | 1 | 1 | 2022 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1